Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas - Takeaways - MDSpire

Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas

  • By

  • Piotr Nowaczyk

  • Dawid Murawa

  • Karol Połom

  • Magdalena Waszyk-Nowaczyk

  • Arkadiusz Spychała

  • Michał Michalak

  • Paweł Murawa

  • March 14, 2012

  • 0 min

Share

  • 1

    Sentinel lymph node biopsy (SLNB) is crucial for assessing lymph node metastasis in colon cancer, impacting treatment decisions and survival rates.

  • 2

    Up to 30% of pN0 colon cancer patients may experience recurrence or metastasis within five years, highlighting the need for accurate lymph node assessment.

  • 3

    Anthropometric features such as BMI and intra-abdominal obesity may affect the efficacy of SLNB in colon cancer, influencing detection rates.

  • 4

    The study analyzed 103 SLNBs performed between 2005 and 2010, focusing on patient demographics and the impact of body composition on biopsy outcomes.

  • 5

    Improved diagnostic techniques, including immunohistochemical staining, may enhance the accuracy of SLNB compared to traditional H&E staining.

Original Source(s)

Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas

  • by Piotr Nowaczyk, Dawid Murawa, Karol Połom, Magdalena Waszyk-Nowaczyk, Arkadiusz Spychała, Michał Michalak, Paweł Murawa

  • March 14, 2012

Related Content

Transumbilical laparoscopic-assisted appendectomy: a feasible minimally invasive option for pediatric acute appendicitis with comparable outcomes to three-port laparoscopic appendectomy

Safety and efficacy of retromuscular-onlay dual-mesh reconstruction for massive abdominal wall defects secondary to abdominal wall endometriosis resection

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.